fa Relationship between anti-apoptotic proteins survivin and Bcl-2, and response to treatment in patients undergoing post-operative RT for laryngeal cancer: a pilot study بیماری های دهان Oral Medicine پژوهشي Research <p> <strong>Background</strong></p><p>  Clinicopathological research has focused on identifying molecular and biological prognostic factors for laryngeal carcinoma (LSCC) treated with post-operative radiotherapy (RT). The aim of this study was to assess the prognostic importance of anti-apoptotic proteins survivin and B-cell lymphoma-2 (Bcl-2) in a series of patients with LSCC who had primary surgery followed by RT. </p><p> <strong>Methods</strong> </p><p> Thirty-three consecutive patients who underwent primary surgery followed by RT were considered. Survivin nuclear and cytoplasmic expressions and Bcl-2 expression were determined immunohistochemically. </p><p> <strong>Results</strong></p><p>  The loco-regional recurrence rate was significantly higher among LSCC patients with a nuclear survivin expression >10.0% (P = 0.029), and their disease-free survival (DFS) was shorter than in cases whose nuclear survivin expression was ≤10.0% (P = 0.002). DFS was significantly shorter in cases with a Bcl-2 expression >2.0% than in those whose Bcl-2 expression was ≤2.0% (P = 0.035). </p><p> <strong>Conclusions</strong></p><p>  Nuclear survivin expression and Bcl-2 expression warrant further investigation as potential predictive biomarkers to enable individualized treatments (e.g. post-operative chemo-radiotherapy instead of RT alone for patients whose LSCCs strongly express nuclear survivin or/and Bcl-2). This preliminary evidence justifies the design of new studies on the association of agents targeting survivin and Bcl-2 with conventional chemotherapeutic agents and RT for advanced LSCC. </p><hr><p></p><p> <strong>Source: </strong>Journal of Oral Pathology & Medicine</p><p><a href="http://onlinelibrary.wiley.com/doi/10.1111/jop.12020/abstract" target="_blank"><font color="#0000ff"> Full Text</font></a></p> Bcl-2;laryngeal carcinoma;post-operative radiotherapy;prognosis;survivin 0 0 http://idai.ir/browse.php?a_code=A-10-32-2257&slc_lang=fa&sid=1 Gino Marioni gino.marioni@unipd.it 100319475328460010668 100319475328460010668 Yes Department of Neurosciences, Otolaryngology Section, University of Padova, Padova, Italy Alberto Staffieri 100319475328460010669 100319475328460010669 No Department of Neurosciences, Otolaryngology Section, University of Padova, Padova, Italy Marco Lionello 100319475328460010670 100319475328460010670 No Department of Neurosciences, Otolaryngology Section, University of Padova, Padova, Italy Giulia Tealdo 100319475328460010671 100319475328460010671 No Department of Neurosciences, Otolaryngology Section, University of Padova, Padova, Italy Claudia Staffieri 100319475328460010672 100319475328460010672 No Department of Neurosciences, Otolaryngology Section, Treviso Branch, University of Padova, Treviso, Italy Luciano Giacomelli 100319475328460010673 100319475328460010673 No Department of Medicine, University of Padova, Padova, Italy Maria Luisa Friso 100319475328460010674 100319475328460010674 No Radiotherapy and Nuclear Medicine Unit, Istituto Oncologico Veneto IOV IRCCS, Padova, Italy Roberto Stramare 100319475328460010675 100319475328460010675 No Department of Medicine, Institute of Radiology, University of Padova, Padova, Italy Giancarlo Ottaviano 100319475328460010676 100319475328460010676 No Department of Neurosciences, Otolaryngology Section, University of Padova, Padova, Italy Stella Blandamura 100319475328460010677 100319475328460010677 No Department of Medicine, University of Padova, Padova, Italy